For instance, anaplastic lymphoma kinase (ALK) rearrangement showed the fusion in approximately 3–6% of NSCLC patients and the overall response rate rose to 57% in ALK-rearranged patients [11–14]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.